We analyzed the clinical characteristics of the 4 cell cycle-related genes involved in CXP treatment of HCC, including CDK4, CHEK1, CCNB1, and CDKN2A, to further evaluate the clinical application value of CXP in HCC treatment. This evidence concerns the gene CDKN2A and hepatocellular carcinoma.